highlighted the usefulness of positron emission tomography (PET)/computed tomography (CT) in patients with suspected cardiovascular implantable electronic device infection (CIED). The following points should be considered before reaching a final conclusion.
Guidelines recommend avoiding fluorodeoxyglucose (FDG)-
PET scans when blood glucose level is Ͼ200 mg% in patients with cancer because hyperglycemia compromises the diagnostic ability by decreasing FDG uptake (2,3). Did the authors make an attempt to study the impact of hyperglycemia on the sensitivity and specificity of the scan because hyperglycemia is common in patients with CIED infection? 2. In the study by Sarrazin et al. (1), how many patients received antibiotic therapy before the scan and for how long of a duration? What was the impact of prior antibiotic therapy on the sensitivity and specificity of the scan? 3. Increased FDG uptake is nonspecific and may be increased in the setting of inflammation, infection, malignancy, or clot formation, whereas it may be decreased in patients with leukopenia even in the presence of infection (4,5).
What is the impact of the scan results on patient management?
This question remains unanswered because the decision to treat was not based on scan findings. Larger-scale prospective studies with longer follow-up periods (to rule out any latent infection) are required before supporting a conservative approach for negative scans in patients with bacteremia.
Considering high scan cost, FDG-PET/CT should only be used as an adjunct diagnostic test in selective patients with CIED in whom routine workup of fever (including transesophageal echocardiography) remains inconclusive. 
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